- The phase I study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of ALM27134*
- ALM27134 has the potential to treat underserved patients with a variety of autoimmune dermatological diseases
BARCELONA, Spain I September 22, 2022 I Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced the initiation of the phase I study evaluating the safety, pharmacokinetics, pharmacodynamics and clinical activity of ALM27134*, a first-in-class fully human, high-affinity monoclonal antibody that targets IL-1RAP (Interleukin-1 Receptor Accessory Protein) for the treatment of autoimmune dermatological diseases. Thus, the first dose for a healthy volunteer in the first-in-human clinical study of ALM27134 has been completed.
ALM27134 targets IL-1RAP, whose blockade simultaneously abrogates multiple disease drivers among the IL-1 family of proinflammatory cytokine receptors, including IL-1R, IL-33R, and IL-36R, differentiating ALM27134 from single cytokine blockade therapies. These cytokines have been implicated in a broad-spectrum of autoimmune conditions, giving ALM27134 great potential to treat underserved patients with a variety of autoimmune dermatological diseases.
“The start of the first clinical study of ALM27134, encourages us to continue working on the testing and development of this high-potential first-in-class treatment. We have the ambition to continue sharing further milestones in the future of this monoclonal antibody” said Karl Ziegelbauer, Ph.D., Almirall’s Chief Scientific Officer
Almirall and Ichnos Sciences signed an exclusive licence agreement for the IL-1RAP antagonist ALM27134 last December, granting Almirall global rights to develop and commercialise this monoclonal antibody for autoimmune diseases. Ichnos Sciences retained rights to antibodies targeting the IL-1RAP pathway for oncology indications.
*Previously referred to as ISB 880.
About Almirall
Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.
The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenues in 2021 were 836.5 million euros.
For more information, please visit almirall.com
SOURCE: Almirall
Post Views: 90
- The phase I study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of ALM27134*
- ALM27134 has the potential to treat underserved patients with a variety of autoimmune dermatological diseases
BARCELONA, Spain I September 22, 2022 I Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced the initiation of the phase I study evaluating the safety, pharmacokinetics, pharmacodynamics and clinical activity of ALM27134*, a first-in-class fully human, high-affinity monoclonal antibody that targets IL-1RAP (Interleukin-1 Receptor Accessory Protein) for the treatment of autoimmune dermatological diseases. Thus, the first dose for a healthy volunteer in the first-in-human clinical study of ALM27134 has been completed.
ALM27134 targets IL-1RAP, whose blockade simultaneously abrogates multiple disease drivers among the IL-1 family of proinflammatory cytokine receptors, including IL-1R, IL-33R, and IL-36R, differentiating ALM27134 from single cytokine blockade therapies. These cytokines have been implicated in a broad-spectrum of autoimmune conditions, giving ALM27134 great potential to treat underserved patients with a variety of autoimmune dermatological diseases.
“The start of the first clinical study of ALM27134, encourages us to continue working on the testing and development of this high-potential first-in-class treatment. We have the ambition to continue sharing further milestones in the future of this monoclonal antibody” said Karl Ziegelbauer, Ph.D., Almirall’s Chief Scientific Officer
Almirall and Ichnos Sciences signed an exclusive licence agreement for the IL-1RAP antagonist ALM27134 last December, granting Almirall global rights to develop and commercialise this monoclonal antibody for autoimmune diseases. Ichnos Sciences retained rights to antibodies targeting the IL-1RAP pathway for oncology indications.
*Previously referred to as ISB 880.
About Almirall
Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.
The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenues in 2021 were 836.5 million euros.
For more information, please visit almirall.com
SOURCE: Almirall
Post Views: 90
